# Nova Ltd. (NVMI) — Stock CV

Nova Ltd. is a $11.2B technology company. Revenue grew 31.0% over the last year, it keeps 29¢ of every dollar of sales as profit, and it holds more cash than debt. It trades at 41.5× earnings — around the middle of its own history.

> Nova Ltd is a provider of metrology and process control solutions used in semiconductor manufacturing.

## Identity

- **Ticker**: NVMI
- **Sector**: Technology
- **Industry**: Semiconductors
- **Employees**: 1 612
- **Website**: https://www.novami.com
- **Market cap**: $11.2B
- **Last price**: $352.47
- **Financial profile**: Strong

## Vitals (FY2025)

- **Revenue**: $881M
- **Net income**: $259M
- **Free cash flow**: $190M
- **Net cash**: $218M
- **P/E**: 41.5
- **Revenue growth (YoY)**: 31.0%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 22 |
| Growth | 100 |
| Profitability | 90 |
| Health | 93 |
| Quality | 75 |
| Moat | 100 |

## Qualifications (beginner checklist) — 10 of 10 passed

- [x] Revenue growing — +31.0% YoY
- [x] Profitable — $259M FY2025
- [x] Profit growing — +54.0% YoY
- [x] Generates cash — $190M FY2025
- [x] Debt under control — more cash than debt
- [x] Established company — $11.2B market cap
- [x] Not printing shares — +9.2% shares over ~5y
- [x] Proven track record — 5/5 profitable years
- [x] Financially stable — Altman Z 7.7 — safe
- [x] Valuation not extreme — P/E 41.5

## Experience (career milestones)

- **2026** — New obesity GLP-1 pills were launched, with patients getting their hands on them from Danish drugmaker Novo
- **FY2025** — Best year on record: $259M net income
- **2025** — Novo acquired Akero Therapeutics for $5.2 billion
- **2024** — Parent company Novo Holdings agreed to acquire Catalent for $16.5 billion
- **2024** — Novo reached a $604 billion market capitalization and became the 12th most valuable company in the world
- **2023** — Novo's market capitalization exceeded the GDP of Denmark's domestic economy
- **2023** — Novo agreed to acquire the Montreal-headquartered pharmaceutical company, Inversago Pharma for $1…
- **2022** — Novo agreed to acquire Forma Therapeutics for $1.1 billion with the intent to expand its sickle…
- **FY2021** — Profitable every year on record: 5 consecutive profitable years in our data
- **FY2021** — Positive free cash flow every year since: 5-year streak
- **1991** — Novo Nordisk Engineering (now NNE) demerged after working as in-house consultants at Novo for years, to…
- **1989** — The corporation was created in 1989, through a merger of two Danish pharmaceutical companies
- **1985** — The company introduced the first insulin pen device called Novopen

## Strengths

- High gross margin (55.6%)
- Strongly profitable — 29.4% net margin
- Revenue growing 31.0% year over year
- Strong cash conversion — FCF is 21.5% of revenue
- Net cash position after subtracting debt from cash

## Watch-outs

- None stand out in the data.

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $416M | $93.1M | $98.2M |
| FY2022 | $571M | $140M | $106M |
| FY2023 | $518M | $136M | $218M |
| FY2024 | $672M | $184M | $218M |
| FY2025 | $881M | $259M | $190M |

---

Source: https://stockcv.com/NVMI — derived from company filings; may be delayed or incomplete. Information, not investment advice.